Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Analytical Science

Going Native with Microfluidics

When it comes to assessing the key characteristics of complex protein-based biotherapeutics, one of the main challenges is analyzing in native conditions. It is important to ensure that the protein is in native or near-native conditions, in solution, with relevant excipients, and that it remains this way throughout the analysis. You also need to ensure that only the protein portion is read, but when you have a complex solution with excipients and additives present, these can interfere with the read.

But we should also acknowledge that proteins don’t always function alone – the interactions of a protein can be instrumental. We need to consider proteins not as isolated entities, but as part of rich, complex networks that ultimately drive biological systems.

In my view, techniques that rely on surface interactions or denaturation just can’t give us a true picture of the protein, but in my microfluidics technology can. At the microfluidic scale turbulence can be readily avoided and so fluid behaviour is more predictable than microfluidic flow. This in turn implies improved reliability and reproducibility of experiments. Importantly, with well-defined flow it is possible to perform experiments in solution instead of surface-bound.  Testing in solution is of course relevant for basic metrics like size, but it becomes even more vital as research shifts to looking at interactions. Often the interactions of a protein with other molecules is key, so being able to observe these without compromise or risk of artefacts is crucial.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Andrew Lynn

Andrew Lynn is CEO, Fluidic Analytics, Cambridge, UK.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register